Lifetech Scientific (01302.HK) to Acquire 96.46% Stake in Beijing Huayi Shengjie for RMB 1.8733 Billion

Intelligent Finance APP, Lifetech Scientific (01302) announced that on May 22, 2026, the company plans to acquire approximately 96.46% of the equity in Starway Medical Co. Ltd (Starway Medical) from the seller AUT-VII HK Holdings Limited. The transaction consideration is approximately RMB 1.8733 billion. The consideration will be paid by the company issuing convertible bonds to the seller. After the completion of the transaction, Starway Medical will become a non-wholly owned subsidiary of the company, and its financial performance will be consolidated into the group’s consolidated financial statements.

As a medical device company, Starway Medical is mainly engaged in the research and development, manufacturing, and sales of vascular interventional medical devices. Starway Medical's products are primarily used for treating congenital heart defects and preventing cardioembolic stroke. In 2003, Starway Medical launched one of the first domestically produced congenital heart disease occluders in China, and in 2009, introduced China’s first patent foramen ovale (PFO) occluder product.

Starway Medical is mainly engaged in the research and development, manufacturing, and sales of vascular interventional medical devices, possessing competitive advantages in proprietary technology, market access, and R&D capabilities. The directors believe that the acquisition of Starway Medical aligns with the group's overall development strategy and will bring long-term benefits to the company.